Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance (CHRONOS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03227926

Recruitment Status : Completed

First Posted : July 24, 2017

Last Update Posted : August 25, 2022

Sponsor:

Information provided by (Responsible Party):

Fondazione del Piemonte per l'Oncologia

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	November 6, 2019
Actual Study Completion Date :	December 31, 2021

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Sartore-Bianchi A, Pietrantonio F, Lonardi S, Mussolin B, Rua F, Crisafulli G, Bartolini A, Fenocchio E, Amatu A, Manca P, Bergamo F, Tosi F, Mauri G, Ambrosini M, Daniel F, Torri V, Vanzulli A, Regge D, Cappello G, Marchiò C, Berrino E, Sapino A, Marsoni S, Siena S, Bardelli A. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat Med. 2022 Aug;28(8):1612-1618. doi: 10.1038/s41591-022-01886-0. Epub 2022 Aug 1.

To Top